JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
List view / Grid view
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
26 June 2015 | By Victoria White
The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)...
11 June 2015 | By Victoria White
The global market value for axial spondyloarthritis therapeutics will expand from $1.5 billion in 2014 to reach $2.9 billion by 2024...
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...
30 July 2012 | By Abbott
The European Commission has approved HUMIRA®...
25 June 2012 | By Abbott
Abbott announced that the CHMP has issued a positive opinion for HUMIRA®...